Tianeptine is a clinically effective atypical antidepressant with distinct neurochemical properties. In this study, we aimed to investigate the contribution of opioid receptors in the antinociceptive effect of tianeptine on visceral pain in awake rats and to differentiate the subtype and the localization (central and/or peripheral) of these opioid receptors involved in this antinociception. Visceromotor response to noxious colorectal distension (CRD) was quantified with electromyographic recordings, obtained from previously implanted electrodes into the external oblique musculature of rats under anesthesia, before and after tianeptine administration. The opioid receptor antagonist naloxone hydrochloride (NLX) and peripherally restricted opioid receptor antagonist naloxone methiodide (NLXM) were administered intravenously 10 min before tianeptine (10 mg/kg, i.v.). The antinociceptive effect of tianeptine was abolished by NLX (1 and 2 mg/kg, i.v.), but was partially reduced by NLXM (1 and 2 mg/kg, i.v.). A µ-opioid receptor-selective dose (0.03 mg/kg, i.v.) of NLX, but not NLXM, significantly inhibited the antinociceptive effect of tianeptine. Our results suggest that antinociceptive effect of tianeptine on CRD-induced visceral nociception in rats involves the activation of both central and peripheral opioid receptors.

1.
Micó JA, Ardid D, Berrocoso E, Eschalier A: Antidepressants and pain. Trends Pharmacol Sci 2006; 27: 348–354.
2.
Sawynok J, Esser MJ, Reid AR: Antidepressants as analgesics: an overview of central and peripheral mechanisms of action. J Psychiatry Neurosci 2001; 26: 21–29.
3.
Onghena P, Van Houdenhove B: Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo-controlled studies. Pain 1992; 49: 205–219.
4.
Saarto T, Wiffen PJ: Antidepressants for neuropathic pain: a Cochrane review. J Neurol Neurosurg Psychiatry 2010; 81: 1372–1373.
5.
Millan MJ: Descending control of pain. Prog Neurobiol 2002; 66: 355–474.
6.
Costa e Silva JA, Ruschel SI, Caetano D, Rocha FL, da Silva Lippi JR, Arruda S, Ozun M: Placebo-controlled study of tianeptine in major depressive episodes. Neuropsychobiology 1997; 35: 24–29.
7.
Defrance R, Marey C, Kamoun A: Antidepressant and anxiolytic activities of tianeptine: an overview of clinical trials. Clin Neuropharmacol 1988; 11:S74–S82.
8.
Uzbay IT, Cinar MG, Aytemir M, Tuglular I: Analgesic effect of tianeptine in mice. Life Sci 1999; 64: 1313–1319.
9.
Muniz PS, Nardi AE: Refractory pain-depression syndrome treated with tianeptine: a case report. Aust N Z J Psychiatry 2004; 38: 176.
10.
Bilge SS, Bozkurt A, Ilkaya F, Ciftcio ğlu E, Kesim Y, Uzbay TI: The antinociceptive effects of intravenous tianeptine in colorectal distension-induced visceral pain in rats: the role of 5-HT3 receptors. Eur J Pharmacol 2012; 681: 44–49.
11.
Lee HG, Choi JI, Yoon MH, Obata H, Saito S, Kim WM: The antiallodynic effect of intrathecal tianeptine is exerted by increased serotonin and norepinephrine in the spinal dorsal horn. Neurosci Lett 2014; 583: 103–107.
12.
Kim WM, Lee SH, Jeong HJ, Lee HG, Choi JI, Yoon MH: The analgesic activity of intrathecal tianeptine, an atypical antidepressant, in a rat model of inflammatory pain. Anesth Analg 2012; 114: 683–689.
13.
Spiegel K, Kalb R, Pasternak GW: Analgesic activity of tricyclic antidepressants. Ann Neurol 1983; 13: 462–465.
14.
Ghelardini C, Galeotti N, Bartolini A: Antinociception induced by amitriptyline and imipramine is mediated by alpha2A-adrenoceptors. Jpn J Pharmacol 2000; 82: 130–137.
15.
Gray AM, Spencer PSJ, Sewell RD: The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds. Br J Pharmacol 1998; 124: 669–674.
16.
Biegon A, Samuel D: Interaction of tricyclic antidepressants with opioid receptors. Biochem Pharmacol 1980; 29: 460–461.
17.
Isenberg KE, Cicero TT: Possible involvement of opioid receptors in the pharmacological profiles of antidepres-sant compounds. Eur J Pharmacol 1984; 103: 57–63.
18.
Sacerdote P, Brini A, Mantegazza P, Panerai AE: A role for serotonin and b-endorphin in the analgesia induced by some tricylic antidepressant drugs. Pharmacol Biochem Behav 1987; 26: 153–158.
19.
Schreiber S, Rigai T, Katz Y, Pick CG: The antinociceptive effect of mirtazapine in mice is mediated through serotonergic, noradrenergic and opioid mechanisms. Brain Res Bull 2002; 58: 601–615.
20.
Schreiber S, Bleich A, Pick CG. Venlafaxine and mirtazapine: different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects – a possible opioid involvement in severe depression? J Mol Neurosci 2002; 18: 143–149.
21.
Schreiber S, Backer MM, Pick CG: The antinociceptive effect of venlafaxine in mice is mediated through opioid and adrenergic mechanisms. Neurosci Lett 1999; 273: 85–88.
22.
Schreiber S, Backer MM, Kaufman JP, Pick CG: Interaction between the tetracyclic antidepressant mianserin HCl and opioid receptors. Eur Neuropsychopharmacol 1998; 8: 297–302.
23.
Su X, Gebhart GF: Effects of tricyclic antidepressants on mechanosensitive pelvic nerve afferent fibers innervating the rat colon. Pain 1998; 76: 105–114.
24.
Michael-Titus A, Costentin J: Analgesic effects of metapramine and evidence against the involvement of endogenous enkephalins in the analgesia induced by tricyclic antidepressants. Pain 1987; 31: 391–400.
25.
İlkaya F, Bilge SS, Bozkurt A, Baş DB, Erdal A, Çiftçioğlu E, Kesim Y: The antinociceptive effect of intravenous imipramine in colorectal distension-induced visceral pain in rats: the role of serotonergic and noradrenergic receptors. Pharmacol Biochem Behav 2014; 122: 1–6.
26.
Ulger F, Bozkurt A, Bilge SS, Ilkaya F, Dilek A, Bostanci MO, Ciftcioglu E, Güldogus F: The antinociceptive effects of intravenous dexmedetomidine in colorectal distension-induced visceral pain in rats: the role of opioid receptors. Anesth Analg 2009; 109: 616–622.
27.
Burton MB, Gebhart GF: Effects of kappa-opioid receptor agonists on responses to colorectal distension in rats with and without acute colonic inflammation. J Pharmacol Exp Ther 1998; 285: 707–715.
28.
Sengupta JN, Snider A, Su X, Gebhart GF: Effects of kappa opioids in the inflamed rat colon. Pain 1999; 79: 175–185.
29.
Su X, Sengupta JN, Gebhart GF: Effects of opioids on mechanosensitive pelvic nerve afferent fibers innervating the urinary bladder of the rat. J Neurophysiol 1997; 77: 1566–1580.
30.
Lutz PE, Kieffer BL: Opioid receptors: distinct roles in mood disorders. Trends Neurosci 2013; 36: 195–206.
31.
Berrocoso E, Rojas-Corrales MO, Micó JA: Non-selective opioid receptor antagonism of the antidepressant-like effect of venlafaxine in the forced swimming test in mice. Neurosci Lett 2004; 363: 25–28.
32.
Eisenach JC, Gebhart GF: Intrathecal amitriptyline: antinociceptive interactions with intravenous morphine and intrathecal clonidine, neostigmine, and carbamylcholine in rats. Anesthesiology 1995; 83: 1036–1045.
33.
Pettersen VL, Zapata-Sudo G, Raimundo JM, Trachez MM, Sudo RT: The synergistic interaction between morphine and maprotiline after intrathecal injection in rats. Anesth Analg 2009; 109: 1312–1317.
34.
Stein C: Peripheral mechanisms of opioid analgesia. Anesth Analg 1993; 76: 182–191.
35.
Su X, Julia V, Gebhart GF: Effects of intracolonic opioid receptor agonists on polymodal pelvic nerve afferent fibers in the rat. J Neurophysiol 2000; 83: 963–970.
36.
Sengupta JN, Su X, Gebhart GF: Kappa, but not mu or delta, opioids attenuate responses to distention of afferent fibers innervating the rat colon. Gastroenterology 1996; 111: 968–980.
37.
Danzebrink RM, Green SA, Gebhart GF: Spinal mu and delta, but not kappa, opioid-receptor agonists attenuate responses to noxious colorectal distension in the rat. Pain 1995; 63: 39–47.
38.
Harada Y, Nishioka K, Kitahata LM, Nakatani K, Collins JG: Contrasting actions of intrathecal U50,488H, morphine, or [D-Pen2, D-Pen5] enkephalin or intravenous U50,488H on the visceromotor response to colorectal distension in the rat. Anesthesiology 1995; 83: 336–343.
39.
Su X, Sengupta JN, Gebhart GF: Effects of kappa opioid receptor-selective agonists on responses of pelvic nerve afferents to noxious colorectal distension. J Neurophysiol 1997; 78: 1003–1012.
40.
Ozaki N, Sengupta JN, Gebhart GF: Differential effects of mu-,delta-, and kappa-opioid receptor agonists on mechanosensitive gastric vagal afferent fibers in the rat. J Neurophysiol 2000; 83: 2209–2216.
41.
Daniel EE, Fox-Threlkeld JET: Role of opioid receptor subtypes in control of the gastrointestinal tract; in Holle GH, Wood JD (eds): Advances in the Innervation of the Gastrointestinal Tract. Michigan, Excerpta Medica, 1992, pp 329–340.
42.
Bagnol D, Mansour A, Akil H, Watson SJ: Cellular localization and distribution of the cloned mu and kappa opioid receptors in rat gastrointestinal tract. Neuroscience 1997; 81: 579–591.
43.
Hamon M, Gozlan H, Bourgoin S, Benoliel JJ, Mauborgne A, Taquet H, Cesselin F, Mico JA: Opioid receptors and neur-op-eptides in the CNS in rats treated chr-onically with amoxapine or amitrip-tyline. Neuropharmacology 1987; 26: 531–539.
44.
Hameroff SR, Cork RC, Scherer K, Crago BR, Neuman C, Womble JR, Davis TP: Doxepin effects on chronic pain, depression and plasma opioids. J Clin Psychiatry 1982; 43: 22–27.
45.
Dziedzicka-Wasylewska M, Dlaboga D, Pierzchała-Koziec K, Rogóz Z: Effect of tianeptine and fluoxetine on the levels of Met-enkephalin and mRNA encoding proenkephalin in the rat. J Physiol Pharmacol 2002; 53: 117–125.
46.
Onali P, Dedoni S, Olianas MC: Direct -agonist activity of tricyclic antide-pressants at distinct opioid receptor subtypes. J Pharmacol Exp Ther 2010; 332: 255–265.
47.
Mochizuki D, Tsujita R, Yamada S, Kawasaki K, Otsuka Y, Hashimoto S, Hattori T, Kitamura Y, Miki N: Neurochemical and behavioural characterization of milnacipran, a serotonin and noradrenaline reuptake inhibitor in rats. Psychopharmacology (Berl) 2002; 162: 323–332.
48.
Gassaway MM, Rives ML, Kruegel AC, Javitch JA, Sames D: The atypical antidepressant and neurorestorative agent tianeptine is a µ-opioid receptor agonist. Transl Psychiatry 2014; 4:e411.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.